Stocktoria
NEOGEN CORP NEOG
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1989-08-23
NEOGEN CORP statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 47.1% | 50.2% | 49.4% | 46.1% | 45.9% |
| Operating margin | -118.6% | 6.3% | 4.6% | 11.1% | 15.8% |
| Net margin | -122.1% | -1.0% | -2.8% | 9.2% | 13.0% |
| Return on assets | -31.7% | -0.2% | -0.5% | 4.9% | 6.6% |
| Return on equity | -52.7% | -0.3% | -0.7% | 5.4% | 7.2% |
| Debt / equity | 0.42× | 0.28× | 0.28× | 0.00× | — |
| Current ratio | 3.32 | 3.82 | 4.03 | 8.05 | 11.03 |
| Revenue growth | -3.2% | 12.4% | 56.0% | 12.5% | 12.0% |
Source: SEC EDGAR filings · CIK 0000711377 · as of 2025-05-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.